Afexa Life Sciences Inc.

Afexa Life Sciences Inc.

March 04, 2005 09:00 ET

CV Technologies Inc.: Canadian Mountaineers Take COLD-fX® to the Top of the World; Announcement of Mt Everest Project Tied to AGM




MARCH 4, 2005 - 09:00 ET

CV Technologies Inc.: Canadian Mountaineers Take
COLD-fX'R' to the Top of the World; Announcement of Mt
Everest Project Tied to AGM

EDMONTON, ALBERTA--(CCNMatthews - March 4, 2005) - CV Technologies Inc.
(CVT) (TSX VENTURE:CVQ) today announced that a Canadian team planning to
scale Mt. Everest will be taking COLD-fX® to strengthen their immune
systems as they take on one of the most hostile environments on the

The climbing expedition is led by Dr. Sean Egan, an accomplished
mountaineer and professor in the School of Human Kinetics at the
University of Ottawa and Peter Luk, Director, School of Business
Management, Ryerson University. Egan is attempting to become the oldest
Canadian to summit the mountain at 29,028 feet. He's been training for
three years.

The announcement was made in conjunction with the Company's Annual
General Meeting in Edmonton where CVT spokesman Don Cherry was presented
with a cheque for $100,000 for the "Rose Cherry Home for Kids".

A portion of the sales of COLD-fX go to the "Rose Cherry Home for Kids".

CV Technologies president and CEO, Dr. Jacqueline Shan said, "This is
another example of COLD-fX helping to protect the health of people who
are in heavy stress situations while engaged in pursuing remarkable
feats. COLD-fX has been used by 26 pro hockey teams and Olympic athletes
and we're pleased it will now be used by mountaineers."

A team of up to 20 climbers will depart Canada for the climb on March
25. Each team member has been given a supply of COLD-fX to help protect
them from colds - a major problem for climbers.

The climb is being sponsored by various Canadian businesses including an
Ottawa based technology company which plans to test some of its products
during the assault.

When the expedition arrives at the base camp, they plan to challenge
other climbers to a game of shinny hockey on the Khumbu Glacier taking
Canadian hockey to new heights. A Russian expedition is planning to be
at the camp at the same time and team leaders hope to create a 2005
Summit Series. The expedition is hauling up regulation size goals in
their gear. Dr. Egan quipped, "All we need now is 'Grapes' to do a
coach's corner." In addition to the game of shinny hockey there will be
a hockey skills competition.

Earlier this week 'players' were given Team Canada jerseys autographed
by Ron Ellis and Paul Henderson to be worn during the 'summit hockey
game' along with toques sporting the name - COLD-fX.

Commenting on the game, Ron Ellis said, "The Team of the Century's
amazing victory in 1972 will now be honoured 'on top of the world'."


Rose Cherry's Home for Kids provides pediatric hospice care and respite
services to families within communities in Ontario, who have children
with life-limiting or life-threatening illness requiring complex and/or
technology-dependent care.


CV Technologies is a biotechnology company founded in 1992. It aims to
become a global leader in the development, distribution, marketing and
selling of safe and effective natural health products for disease
prevention and health maintenance. CVT's lead product - COLD-fX®,
strengthens the immune system and is widely used as a leading anti-cold,
anti-flu treatment.

This news release contains forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ materially
from the statements made. For this purpose, any statements that are
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the foregoing,
the words "believes", "anticipates", "plans", "intends", "expects" and
similar expressions are intended to identify forward-looking statements.
Such risks and uncertainties include, but are not limited to, the need
for capital, changing market conditions, completion of clinical trials,
patient enrolment rates, uncertainty of pre-clinical, retrospective and
early clinical trial results, the establishment of manufacturing
processes and new corporate alliances, the timely development,
regulatory approval and market acceptance of the Company's products, and
other risks detailed from time to time in the Company's filings with
Canadian securities authorities.


Contact Information